KR102519415B1 - Composition for preventing or treating vaginitis - Google Patents

Abstract

The present invention relates to a composition for preventing or treating vaginitis in which Lactobacillus rhamnosus and Lactobacillus acidophilus are mixed in a certain ratio, and by using the composition for preventing or treating vaginitis of the present invention, Candida albicans strains are suppressed and vulvar odor can be removed.

Description

Composition for preventing or treating vaginitis {Composition for preventing or treating vaginitis}

The present invention relates to a composition for preventing or treating vaginitis, and more particularly, to a composition for preventing or treating vaginitis containing Lactobacillus rhamnosus and Lactobacillus acidophilus.

The microbial environment in a woman's vagina is very important to women's health. In particular, because the female vulva is close to the anus and a moist and warm environment is maintained by secretions, it is a very good environment for pathogens to grow. Lactic acid bacteria reside inside the vagina and release lactic acid and other antibacterial substances during the growth process to maintain an optimal vaginal pH of 4.5 or less to suppress the growth of pathogenic strains. However, when these lactic acid bacteria lose their dominance by various bacteria such as anaerobic bacteria or candida, the balance of the microbial environment in the vagina is disturbed, increasing the possibility of getting vaginitis.

Vaginitis causes premature birth, low birth weight, and weakens the immune system. Vaginitis in women is largely classified into three types: Bacterial vaginosis caused by bacterial infection, Vulvovaginal candidiasis caused by Candida fungi, and Trichomonas vaginitis caused by infection with the protozoan Trichomonas. Bacterial vaginosis is a disease in which the acidity of the vagina increases and the microbial environment changes due to the growth of specific bacteria in the female vagina. It is one of the most common inflammations in women of childbearing age, usually with increased white or off-white vaginal discharge and odor.

As antibiotics used to treat bacterial vaginosis, metronidazole and clindamycin, which are susceptible to anaerobic strains, are commonly used. Metronidazole affects the DNA replication mechanism, and clindamycin affects the protein synthesis process, preventing bacteria from multiplying. However, the use of these antibiotics may affect the survival of not only pathogenic bacteria but also beneficial lactic acid bacteria. In particular, care should be taken as it affects the lactobacilli in the vagina.

Candida vaginitis is a common disease that 75% of women experience at least once in their lifetime, and 45% of women experience it at least twice a year. Candida albicans, a fungus, is the causative agent, and when antibiotics are used for a long time, or when there is pregnancy or diabetes, the concentration of lactic acid bacteria and normal vaginal bacteria in the vagina is lowered, resulting in overgrowth of fungi, resulting in this disease. Symptoms of candida vaginitis include itching of the vulva, vaginal discharge with a bad odor, pain during sexual intercourse, pain during urination, etc., and are treated by taking antifungal drugs or inserting vaginal tablets. May cause complications, etc. In addition, Candida vaginitis often recurs, in which case persistent vulvar itching occurs.

Recently, orally administered lactic acid bacteria have been used to prevent vaginitis and improve vaginal health. If you take lactic acid bacteria regularly, the lactic acid bacteria survives through the intestines and into the vagina, and after settling, proliferates as beneficial bacteria necessary for vaginal health. However, since the ingested lactic acid bacteria must pass through the digestive tract, there is a problem in that the number of guaranteed bacteria settled in the vagina is small compared to the number of injected bacteria.

In addition, in order to create a stable vaginal microbial environment and effective sterilization of pathogenic bacteria, above all, the number of lactobacillus species, dominant species, core species and their colony ratio in the vaginal flora, and the total number of lactic acid bacteria that are particularly effective against vaginitis-causing bacteria such as Candida A study on the characteristics is needed.

Lactobacillus rhamnosus is a gram-positive lactic acid bacterium most commonly found in the healthy female genital tract-urinary tract. It is known as a strain that helps and contributes to basic colon health.

Lactobacillus acidophilus is a microorganism found in the oral cavity, intestine, and vagina. It has strong acid resistance and bile resistance, so it has high intestinal viability and high anchorage to the intestinal wall, so it is beneficial to live in the intestine for a long time. It works. In the vagina, it maintains an appropriate acidic environment to inhibit the growth of harmful bacteria. It is also known to have antibacterial action by producing natural antibiotics such as acidolin, acidophillin, lactobacillin, and lactocin.

Meanwhile, betulin (Betulin) is a natural triterpene, found in abundance in the bark and sap of birch trees, and is known to protect trees from overheating by the sun. Recent studies have shown that betulin initiates the apoptotic process of tumor cells and slows the growth of tumor cells (Alkurtti et al., 2006), and also inhibits the maturation of sterol regulatory element binding protein (SREBP), thereby reducing cholesterol and fatty acids. has been shown to reduce the biosynthesis of , improve obesity, and reduce the size of atherosclerotic plaques (Tang et al., 2011). However, the mixing action of betulin with lactic acid bacteria or its effect on vaginal health is unknown.

Korean Patent Registration No. 2139687 has Gardnerella vaginalis ( GardnerelLa vaginalis ) and Candida albicans ( Candida albicans ) Lactobacillus rhamnosus ( Lactobacillus rhamnosus ) strain MG4288 having antibacterial activity (accession number KCTC13823BP), strain culture medium and cell-free supernatant of the strain are described. In addition, Korean Patent Registration No. 1098241 discloses Lactobacillus sp. having an activity to inhibit urinary tract infection and candida vaginitis. H. Y 7801 and products containing it as an active ingredient are described, and Korean Patent Registration No. 1784847 relates to a composition containing salt, sugar and lactic acid bacteria, salt selected from molten salt, refined salt or sun salt; (2) sugars such as xylose and arabinose; And (3) Lactobacillus acidophilus; KCTC No.3164), Bifidobacterium longum subspecies longum ( Bifidobacterium longum subsp. longum; KCTC No. 3128), Streptococcus sp (KCTC No.5644) and Bacillus cereus (KCTC No. 13123) strains, and prevention of vaginitis containing a combination consisting of one or more lactic acid bacteria selected from the group consisting of as an active ingredient A pharmaceutical composition for treatment is described. However, these lactic acid bacteria compositions are not described in the strong antibacterial activity by the optimal combination of vaginal lactic acid bacteria disclosed in the present invention.

Korea Patent No. 2139687, Lactobacillus MG4288 for treatment or improvement of vaginitis having antibacterial effect on Gardnerella vaginalis and Candida albicans, registered on July 24, 2020. Korea Patent No. 1717672, Lactobacillus sp. having activity to inhibit urinary tract infection and candida vaginitis. HY 7801 and products containing it as an active ingredient, registered on December 19, 2011. Korean Patent Registration No. 1784847, composition containing lactic acid bacteria for preventing and treating vaginitis and its use, registered on September 28, 2017.

Alakurtti, Sami; Mkel, Taru; Koskimies, Salme; Yli-Kauhaluoma, Jari (September 2006). "Pharmacological properties of the ubiquitous natural product betulin". European Journal of Pharmaceutical Sciences. 29 (1): 1-13. Tang, Jing-Jie; Li, Jia-Gui; Qi, Wei; Qiu, Wen-Wei; Li, Pei-Shan; Li, Bo-Liang; Song, Bao-Liang (2011). "Inhibition of SREBP by a Small Molecule, Betulin, Improves Hyperlipidemia and Insulin Resistance and Reduces Atherosclerotic Plaques". Cell Metabolism. 13 (1): 44-56.

Alakurtti, Sami; Mkel, Taru; Koskimies, Salme; Yli-Kauhaluoma, Jari (September 2006). "Pharmacological properties of the ubiquitous natural product betulin". European Journal of Pharmaceutical Sciences. 29 (1): 1-13. Tang, Jing-Jie; Li, Jia-Gui; Qi, Wei; Qiu, Wen-Wei; Li, Pei-Shan; Li, Bo-Liang; Song, Bao-Liang (2011). "Inhibition of SREBP by a Small Molecule, Betulin, Improves Hyperlipidemia and Insulin Resistance and Reduces Atherosclerotic Plaques". Cell Metabolism. 13 (1): 44-56.

It is to provide a vaginitis prevention or composition containing Lactobacillus rhamnosus and Lactobacillus acidophilus.

The present invention relates to a composition for preventing or treating vaginitis, and provides a composition for preventing or treating vaginitis containing Lactobacillus rhamnosus and Lactobacillus acidophilus. The Lactobacillus rhamnosus and Lactobacillus acidophilus are preferably Lactobacillus rhamnosus HN001 and Lactobacillus acidophilus La-14.

The Lactobacillus rhamnosus HN001 ( Lactobacillus rhamnosus HN001) and Lactobacillus acidophilus La-14 ( Lactobacillus acidophilus La-14) may be mixed in a ratio of 1:2 to 6, preferably 1:4 They can be mixed in any proportion.

The Lactobacillus rhamnosus HN001 ( Lactobacillus rhamnosus HN001) and Lactobacillus acidophilus La-14 ( Lactobacillus acidophilus La-14) mixed strains may be included in an amount of 1 to 50% (hereinafter, weight %) based on the total weight of the composition. . Although not limited thereto, if the mixed strain is less than 1% based on the total weight of the composition, it may not exhibit antifungal activity against Candida strains, and if it exceeds 50%, the effect of the concentration used may not be economical.

The composition for preventing or treating vaginitis of the present invention is characterized by having an effect of removing odor from the vulva. The odor of the vulva can be caused by bacterial vaginosis, an increase in secretions with an unpleasant odor caused by yeast infections such as Candida, and odors caused by bacteria growing in synthetic fiber underwear. It is a common phenomenon experienced by most women. The composition for preventing or treating vaginitis of the present invention can remove the odor of the vulva by reducing the concentration of ammonia or trimethylamine, which causes the odor of the vulva.

The composition for preventing or treating vaginitis may further include betulin. Betulin is a triterpene derived from birch trees and is known to lower cholesterol levels, help prevent obesity, and improve insulin sensitivity. In addition, it has been confirmed that skin wrinkles are improved through the effect of promoting cell regeneration and collagen production by inhibiting collagenase activity. In addition, betulin can be obtained from chaga mushrooms, hwangchil tree extracts, etc., in addition to birch trees, and can also be chemically synthesized.

According to one embodiment of the present invention, the betulin may be included in an amount of 0.01 to 20% (hereinafter referred to as weight %) based on the total weight of the composition. Although not limited thereto, if betulin is less than 0.01% based on the total weight of the composition, the effect of increasing the antifungal activity against Candida strains of Lactobacillus rhamnosus HN001 and Lactobacillus acidophilus La-14 mixed strain by betulin is increased. It may be insignificant, and if it exceeds 20%, the activity of the mixed strain of Lactobacillus rhamnosus HN001 and Lactobacillus acidophilus La-14 may decrease. Preferably, 0.01 to 10% may be included, and more preferably 0.2 to 2% may be included.

The composition for preventing or treating vaginitis of the present invention is characterized by inhibiting Candida albicans strains. By inhibiting the Candida albicans strain, it is possible to remove the vulvar odor caused by vaginitis caused by Candida. In particular, vaginitis caused by Candida is often accompanied by unbearable itching of the vulva, and the composition for preventing or treating vaginitis of the present invention can alleviate itching by inhibiting Candida albicans strains.

The composition for preventing or treating vaginitis may further include alpha-glucan oligosaccharide. Alpha-glucan oligosaccharide can be provided as feed for Lactobacillus rhamnosus and Lactobacillus acidophilus, and itself increases the antifungal effect against Candida strains of Lactobacillus rhamnosus and Lactobacillus acidophilus It can be used to soften and moisturize the skin. According to one embodiment of the present invention, the alpha-glucan oligosaccharide may be included in an amount of 0.01 to 15% (hereinafter referred to as weight %) based on the total weight of the composition. If alpha-glucan oligosaccharide is less than 0.01% relative to the total weight of the composition, the effect of increasing antifungal activity against Candida strains of mixed strains of Lactobacillus rhamnosus HN001 and Lactobacillus acidophilus La-14 by betulin may be insignificant. If it is present and exceeds 15%, the activity of the mixed strain of Lactobacillus rhamnosus HN001 and Lactobacillus acidophilus La-14 may be reduced. It may be preferably included in the range of 0.01 to 10%, and more preferably in the range of 0.15 to 1.5%.

The composition for preventing or treating vaginitis of the present invention may be provided for oral or parenteral use, and in the case of a parenteral composition, it is provided as one selected from the group consisting of a cleaning composition, a preparation for vaginal insertion, a sanitary product application agent, or a skin application agent. It can be. In addition, the parenteral composition may be provided as one formulation selected from the group consisting of liquid formulations, solid formulations, suppositories, tablets, lyophilized formulations, granules, and powder formulations.

The composition for preventing or treating vaginitis of the present invention may be prepared as a vulvar cleanser or feminine cleanser, and the topical cleanser or feminine cleanser may include a moisturizer, conditioning agent, thickener, neutralizer, colorant, flavoring agent, emollient, thickener, nutrient, foaming agent, It may contain an organic disinfectant or the like, or may further include a surfactant having detergency.

The composition for preventing or treating vaginitis of the present invention may be provided in the form of a solid formulation, tablet or powder. The composition for preventing or treating vaginitis of the present invention is preferably in powder form, and may be used by mixing with purified water.

In addition, the composition for preventing or treating vaginitis containing Lactobacillus rhamnosus and Lactobacillus acidophilus of the present invention may be provided as a health functional food for preventing or improving vaginitis. At this time, the health functional food for preventing or improving vaginitis may contain Lactobacillus rhamnosus and Lactobacillus acidophilus at a certain ratio and settle in the female vagina through the gastrointestinal tract. The health functional food for preventing or improving vaginitis of the present invention can suppress the Candida albicans strain, which is a causative agent of vaginitis, by being settled in the female vagina, and can help to remove odor from the vulva.

The Lactobacillus rhamnosus and Lactobacillus acidophilus are preferably Lactobacillus rhamnosus HN001 and Lactobacillus acidophilus La-14. In addition, the Lactobacillus rhamnosus HN001 ( Lactobacillus rhamnosus HN001) and Lactobacillus acidophilus La-14 ( Lactobacillus acidophilus La-14) may be mixed in a ratio of 1:2 to 6, preferably 1: mixed in a ratio of 4.

The health functional food for preventing or improving vaginitis may further include betulin. The betulin may be included in an amount of 0.01 to 20% (hereinafter referred to as weight %) based on the total weight of the composition.

In the health functional food for preventing or improving vaginitis, the Lactobacillus rhamnosus and Lactobacillus acidophilus mixed lactic acid bacteria are preferably 0.001 to 30% by weight, more preferably 0.001 to 50% by weight, based on the total weight of the food. Most preferably, it may be added as 0.001 to 90% by weight. The health functional food for preventing or improving vaginitis includes the form of tablets, capsules, pills or liquids, and as foods to which the extract of the present invention can be added, for example, various foods, beverages, gum, There are teas, vitamin complexes, and health functional foods.

The present invention relates to a composition for preventing or treating vaginitis, and by mixing Lactobacillus rhamnosus and Lactobacillus acidophilus in a certain ratio, Candida albicans strains can be suppressed and odor of the vulva can be removed, thereby improving women's quality of life It can help improve and improve your health.

1 is a graph showing the inhibitory action against Candida albicans according to the mixing ratio of Lactobacillus rhamnosus and Lactobacillus acidophilus .
Figure 2 is a graph showing the inhibitory action on Candida albicans according to the mixing ratio of Lactobacillus rhamnosus , Lactobacillus acidophilus and betulin.

Hereinafter, preferred embodiments of the present invention will be described in detail. However, the present invention is not limited to the embodiments described herein and may be embodied in other forms. Rather, the disclosure herein is provided so that it will be thorough and complete, and will fully convey the spirit of the invention to those skilled in the art.

< Example One. Lactobacillus Rhamnosus and Lactobacillus acidophilus Vaginitis Causative Bacteria Suppression Performance Test>

1.1. Lactobacillus Rhamnosus and Lactobacillus acidophilus Vaginitis causative bacteria inhibitory performance test of mixed composition

Lactobacillus rhamnosus and Lactobacillus acidophilus are lactic acid bacteria found in the vagina of healthy women. These affect the secretion of lactic acid and the vaginal pH environment, respectively, and are known to exhibit a certain inhibitory effect on the growth of Candida albicans , which is known as a causative agent of vaginitis. However, while the present inventors were studying the relationship between the characteristics of the microbial flora in the vagina and vaginal health, they showed a great difference in the bactericidal effect on the causative agent of vaginitis according to the mixing ratio of the lactic acid bacteria strain, and in some cases, the fact that the growth of the causative agent of vaginitis is promoted found In particular, when mixing Lactobacillus rhamnosus and Lactobacillus acidophilus at a certain ratio among these mixed strains, it was confirmed that the growth inhibitory effect on Candida albicans was remarkably increased, and the present invention was completed.

The above-described synergistic effect on Candida albicans inhibitory activity is very useful industrially as it can effectively prevent vaginitis even with a small total bacterial count when applied daily as well as a quick therapeutic effect when vaginitis occurs.

The inventors of the present invention extensively screened lactic acid bacteria distributed in the vagina of healthy women , Lactobacillus rhamnosus and Lactobacillus acidophilus showing a certain inhibitory effect on Candida albicans even when used alone was selected, and the bacteria used in the present invention are shown in Table 1 below.

number scientific name strain No. One Lactobacillus rhamnosus HN001 No. 2 Lactobacillus acidophilus La-14 No. 3 Candida albicans ATCC 10231

First, Candida albicans albicans , ATCC 10231) was inoculated into a Potato Dextrose agar (PDA) medium, pre-cultured at 25° C. for 2 days, and then a 10 ⁶ CFU/ml bacterial solution was prepared using sterile physiological saline.

strain sample Con. One 2 3 4 5 6 7 8 9 10 11 HN001 - One - One One One One One 2 4 6 8 La-14 - - One One 2 4 6 8 One One One One

According to the ratio, as shown in Table 2, Lactobacillus rhamnosus HN001 and Lactobacillus acidophilus La-14 were homogenized by adding distilled water to a final concentration of 2×10 ⁶ CFU/ml to prepare test solutions. After that, Candida albicans in the test solution After adding and mixing 0.1 ml of the bacterial solution, cultured at 25 ° C for 24 hours, the number of viable cells was measured by the dilution culture method, and Candida albicans The survival rates of the strains are shown in FIG. 1 . At this time, the group in which the Candida albicans strain was added to sterile physiological saline was used as a control group. Candida albicans The survival rate of the strain immediately after inoculation was determined by Candida albicans The number of bacteria after culturing for 24 hours with the strain as 100% was shown.

As shown in FIG. 1 , Lactobacillus rhamnosus HN001 and Lactobacillus acidophilus La-14 independently exhibited inhibitory effects against Candida albicans strains. In particular, it was confirmed that when Lactobacillus rhamnosus HN001 was used alone, it inhibited the growth of Candida by about 41.2% compared to the control group.

Lactobacillus rhamnosus strain is a lactic acid bacterium found in the vagina of healthy women, and is a strain used for vaginitis. However, since the use of lactic acid bacteria for vaginitis is known to be helpful in preventing recurrence after the use of antibiotics, it is difficult to expect the removal of pathogenic bacteria that cause vaginitis only with the lactic acid bacteria. In addition, it is advantageous to utilize complex lactic acid bacteria to stably establish a healthy vaginal flora after using antibiotics. However, even beneficial lactic acid bacteria show a great difference in their effects depending on the condition of the bacteria mixture. Accordingly, the present inventors increased the inhibitory activity of the causative agent of vaginitis by mixing with Lactobacillus rhamnosus , searched for lactic acid bacteria species capable of establishing a healthy vaginal bacterial flora, and confirmed the mixing ratio.

As shown in Figure 1 , Lactobacillus acidophilus La-14 showed an effect of killing Candida bacteria by about 8.2% compared to the control group. Lactobacillus acidophilus La-14 is a Gram-positive bacterium of the genus Lactobacillus, which is found in the gastrointestinal tract and mouth of humans and animals, and is commercially used in many dairy products together with Streptococcus thermophilus and Lactobacillus delbrueckii subsp. According to FIG. 1, when Lactobacillus acidophilus La-14 was mixed with Lactobacillus rhamnosus HN001, the inhibitory effect on Candida greatly varied depending on the mixing ratio. That is, when Lactobacillus rhamnosus HN001 and Lactobacillus acidophilus La-14 were mixed at a ratio of 1:1, the inhibitory effect of Candida strains was superior to that of the control group, and the effect was superior to that of Lactobacillus acidophilus La-14 strain alone, but Lactobacillus rhamnosus HN001 treatment alone did not show the same inhibitory effect on Candida strains.

In addition, when Lactobacillus rhamnosus HN001, which has a relatively excellent inhibitory effect on Candida strains, was mixed at a higher ratio (2-8:1) than Lactobacillus acidophilus La-14, the survival rate of Candida strains increased rather than the control group. . These results can be interpreted as creating an environment favorable to the survival of Candida strains under certain conditions while growing in a mixture of various types of lactic acid bacteria.

However, when Lactobacillus acidophilus La-14 was mixed at a higher ratio (1:2~8 ) than Lactobacillus rhamnosus HN001, it showed higher Candida strain inhibitory activity compared to the control group. In the case of 2 to 6, Candida inhibitory activity was very high. In particular, when the mixing ratio was 1:4, the survival rate of Candida strain was significantly reduced compared to the case of single treatment with Lactobacillus rhamnosus HN001. This suggests that growth conditions composed of a certain mixing ratio of beneficial lactic acid bacteria can provide an environment capable of synergistically suppressing the activity of Candida strains, one of the causative bacteria of vaginitis.

1.2. Lactobacillus Rhamnosus , Lactobacillus Acidophilus and betulin Vaginitis causative bacteria inhibitory performance test of mixed composition

As shown in Example 1.1, the antifungal effect against Candida strains can be maximized while directly applying Lactobacillus rhamnosus and Lactobacillus acidophilus mixed at a ratio of 1:4 with the highest inhibitory activity of Candida strains to the female vulva. Possible compositions were screened.

As a result of mixing and applying polysaccharides as food for lactic acid bacteria such as Lactobacillus rhamnosus or Lactobacillus acidophilus, samples for skin protection and regeneration, anti-inflammatory, antibacterial natural products, skin tone improving cosmetics, etc. with the strain mixture, betulin and It was confirmed that alpha-glucan oligosaccharide maintained a stable liquid or powder formulation without inhibiting the growth of a 1:4 mixed strain of Lactobacillus rhamnosus and Lactobacillus acidophilus. Thereafter, the antifungal activity of the mixed strain of Example 1.1 and the mixture of betulin and alpha-glucan oligosaccharide against Candida albicans was confirmed.

Betulin is a triterpene derived from birch trees and is known to lower cholesterol levels, help prevent obesity, and improve insulin sensitivity. In addition, it has been confirmed that skin wrinkles are improved through the effect of promoting cell regeneration and collagen production by inhibiting collagenase activity. However, when betulin was used with the mixed strains of Lactobacillus rhamnosus and Lactobacillus acidophilus of the present invention, it was confirmed that the antifungal activity against Candida strains was increased.

As in Example 1.1, Candida albicans albicans , ATCC 10231) was inoculated into Potato Dextrose agar (PDA) medium and pre-cultured at 25℃ for 2 days, and then 10 ⁶ CFU/ml Candida albicans using sterile physiological saline A bacterial solution was prepared. In addition, distilled water was added to obtain Lactobacillus rhamnosus HN001 4×10 ⁴ CFU/ml and Lactobacillus acidophilus La-14 1.6×10 ⁵ CFU/ml, and homogenized 1:4 strain mixture 2×10 ⁵ CFU/ml test solution was prepared, Samples A, B, C and D were prepared by mixing betulin and alpha-glucan oligosaccharide as shown in Table 3 below.

HN001 (cfu/ml) La-14 (cfu/ml) betulin alpha-glucan oligosaccharide survival rate (%) control group - - - - 92.86 A 4×10 ⁴ 1.6×10 ⁵ - - 76.28 B 4×10 ⁴ 1.6×10 ⁵ 2 % - 48.65 C 4×10 ⁴ 1.6×10 ⁵ - 1.5% 60.27 D 4×10 ⁴ 1.6×10 ⁵ 2 % 1.5% 45.67

Then, Candida in the samples A, B, C and D albicans After adding and mixing 0.1 ml of the bacterial solution, cultured at 25 ° C for 24 hours, the number of viable cells was measured by the dilution culture method, and Candida albicans The number of strains was converted into survival rate (%) relative to the initial number of bacteria and shown in Table 3 and FIG . At this time , Candida in sterile physiological saline albicans The group to which the strain was added was used as a control group (Con.).

As shown in Table 4 and FIG. 2 , 2 × 10 ⁵ CFU / ml of Lactobacillus rhamnosus and Lactobacillus acidophilus mixed strain mixed at 1:4 Candida The number of albicans bacteria was inhibited by about 25%. In the case of sample B in which 2% (w/v) of betulin was added, the antifungal effect of the mixed strains of Lactobacillus rhamnosus and Lactobacillus acidophilus against Candida strains was increased by 36% or more.

In the case of adding 1.5% (w/v) of alpha-glucan oligosaccharide that can be provided as food for lactic acid bacteria such as Lactobacillus rhamnosus or Lactobacillus acidophilus (C), Lactobacillus rhamnosus and Lactobacillus acidophilus The antifungal effect of the pilus mixed strain against Candida strains was increased by more than 20%. In addition, when adding betulin 2% (w / v) and alpha-glucan oligosaccharide 1.5% (w / v) to the Lactobacillus rhamnosus and Lactobacillus acidophilus mixed strains mixed together at a ratio of 1:4 (D), there was no significant difference from the betulin additionally administered group (B), but there was a tendency to increase the antifungal effect against Candida strains than the betulin additionally administered group (B).

Through the above results, the Lactobacillus rhamnosus and Lactobacillus acidophilus mixed strains mixed at a ratio of 1:4 according to the present invention showed a significant increase in antifungal activity against Candida strains at a specific mixing ratio, and betulin and / Or it was confirmed that the antifungal effect of the mixed strains of Lactobacillus rhamnosus and Lactobacillus acidophilus mixed at a ratio of 1:4 was increased by adding alpha-glucan oligosaccharide.

< Example 2. Lactobacillus Rhamnosus and Lactobacillus acidophilus Deodorization Performance Test of Mixed Composition>

Vaginitis, such as bacterial vaginosis and candida vaginitis, is particularly stressful for women with an unpleasant smell of vaginal discharge. The present inventors tested the deodorizing performance of a 1:4 mixture of Lactobacillus rhamnosus HN001 and Lactobacillus acidophilus La-14, which had the most excellent Candida strain inhibitory effect, and a sample to which betulin was added.

The deodorization performance was confirmed according to the measurement of ammonia or trimethylamine concentration reduction rate in the EL608 deodorant test method, which is an environmental label certification standard of the Ministry of Environment. After adjusting the concentration of ammonia or trimethylamine diluted with acetone in the test container to the vicinity of the initial concentration (C _b,i ) according to the certification standard, Lactobacillus rhamnosus HN001 and Lactobacillus acidophilus La-14 (1:4 mixing ratio) mixed strain 2 ×10 ⁵ CFU/ml or Lactobacillus rhamnosus HN001 and Lactobacillus acidophilus La-14 (1:4 mixing ratio) mixed strain 2×10 ⁵ CFU/ml with 2% (w/v) betulin added to the sample in the test container Injection was injected through the nozzle. After 6 hours had elapsed after the injection of each sample, the gas in the test vessel was collected with a gas sampler specified in SPS-KCLI2218-6218, and the concentration (C _t,i ) of ammonia or trimethylamine as an odor component was measured. At this time, the gas sampler was used by inserting a direct reading detector tube corresponding to the odor component to be measured and the expected concentration range.

Deodorization performance (odor component concentration reduction rate) was calculated according to the following equation, and the results are shown in Table 4 .

Odor component concentration reduction rate (%) =

Test Items (Concentration reduction rate %) note HN001+La-14 HN001+La-14+betulin ammonia 60.0 54.8 (21.3±0.6)℃
(50.1±0.6)% RH trimethylamine 62.5 57.3

As shown in Table 4 , it was confirmed that the 1:4 mixed strain of Lactobacillus rhamnosus HN001 and Lactobacillus acidophilus La-14, which had the highest Candida strain inhibitory effect, showed an effect of reducing both ammonia and trimethylamine concentrations by more than 60%. . Also Lactobacillus When more betulin was added to the 1:4 mixed strain of rhamnosus HN001 and Lactobacillus acidophilus La-14, it was confirmed that the deodorizing effect increased.

As can be seen from the above results, the 1:2 to 6 mixture of Lactobacillus rhamnosus HN001 and Lactobacillus acidophilus La-14 of the present invention was compared to the mixture of Lactobacillus rhamnosus HN001 and Lactobacillus acidophilus La-14 at a different ratio, and Candida albicans, a causative agent of vaginitis, In addition to the excellent inhibitory effect, it has the effect of directly reducing the concentration of ammonia and trimethylamine, and when betulin was added to this, it was confirmed that the Candida albicans antifungal effect and deodorizing effect were further increased.

< formulation example 1. Manufacture of health functional food for preventing or improving vaginitis>

2g of 1:4 mixture of Lactobacillus rhamnosus HN001 and Lactobacillus acidophilus La-14 of the present invention, betulin 40mg, appropriate amount of vitamin mixture, vitamin A acetate 70μg, vitamin E 1.0mg, vitamin B1 0.13mg, vitamin B2 0.15mg, vitamins B6 0.5mg, Vitamin B12 0.2μg, Vitamin C 10mg, Biotin 10μg, Nicotinamide 1.7mg, Folic Acid 50μg, Calcium Pantothenate 0.5mg, Mineral Mixture Appropriate amount, Ferrous Sulfate 1.75mg, Zinc Oxide 0.82mg, Magnesium Carbonate 25.3mg, monobasic potassium phosphate 15mg, dibasic calcium phosphate 55mg, potassium citrate 90mg, calcium carbonate 100mg, magnesium chloride 24.8mg was prepared into granules, but it can be prepared by transforming into various formulations depending on the use. . In addition, the composition ratio of the vitamin and mineral mixture may be arbitrarily modified, and it may be prepared by mixing the above components according to a conventional health functional food manufacturing method.

Claims (13)

Vaginitis prevention or In the therapeutic composition,
The composition for preventing or treating vaginitis further comprises betulin,
The composition for preventing or treating vaginitis is a composition for preventing or treating vaginitis, characterized in that for inhibiting Candida albicans strains. delete According to claim 1,
The Lactobacillus rhamnosus HN001 ( Lactobacillus rhamnosus HN001) and Lactobacillus acidophilus La-14 ( Lactobacillus acidophilus La-14) are mixed in a ratio of 1: 4 Vaginitis prevention or treatment composition. According to claim 1 or 3,
The composition for preventing or treating vaginitis is a composition for preventing or treating vaginitis, characterized in that it has an effect of removing the odor of the vulva. According to claim 4,
The odor removal of the vulva is a composition for preventing or treating vaginitis, characterized in that to reduce the concentration of ammonia or trimethylamine. delete According to claim 1 or 3,
The composition for preventing or treating vaginitis is a composition for preventing or treating vaginitis, characterized in that provided for oral or parenteral use. According to claim 7
The parenteral composition is a composition for preventing or treating vaginitis, characterized in that one selected from the group consisting of a cleaning composition, a preparation for vaginal insertion, a sanitary product coating agent or a skin coating agent. According to claim 7
The parenteral composition is a composition for preventing or treating vaginitis, characterized in that one selected from the group consisting of liquid formulations, solid formulations, suppositories, tablets, lyophilized formulations, granules and powder formulations. Prevention of vaginitis characterized by comprising a mixed strain of Lactobacillus rhamnosus HN001 and Lactobacillus acidophilus La-14 in a ratio of 1:2 to 6 Or in the health functional food for improvement,
The health functional food for preventing or improving vaginitis further comprises betulin,
The composition for preventing or treating vaginitis is a health functional food for preventing or improving vaginitis, characterized in that for inhibiting Candida albicans strains. delete According to claim 10,
The Lactobacillus rhamnosus HN001 ( Lactobacillus rhamnosus HN001) and Lactobacillus acidophilus La-14 ( Lactobacillus acidophilus La-14) are mixed in a ratio of 1: 4, characterized in that for prevention or improvement of vaginitis health function food. delete

Images